%0 Journal Article
%T The psychosocial impact of prostate cancer screening for BRCA1 and BRCA2 carriers.
%A Bancroft EK
%A Page EC
%A Brook MN
%A Pope J
%A Thomas S
%A Myhill K
%A Helfand BT
%A Talaty P
%A Ong KR
%A Douglas E
%A Cook J
%A Rosario DJ
%A Salinas M
%A Buys SS
%A Anson J
%A Davidson R
%A Longmuir M
%A Side L
%A Eccles DM
%A Tischkowitz M
%A Taylor A
%A Cruellas M
%A Ballestero EP
%A Cleaver R
%A Varughese M
%A Barwell J
%A LeButt M
%A Greenhalgh L
%A Hart R
%A Azzabi A
%A Jobson I
%A Cogley L
%A Evans DG
%A Rothwell J
%A Taylor N
%A Hogben M
%A Saya S
%A  
%A Eeles RA
%A Aaronson NK
%J BJU Int
%V 0
%N 0
%D 2024 Jun 5
%M 38839570
%F 5.969
%R 10.1111/bju.16432
%X <B>OBJECTIVE: </B>To report the long-term outcomes from a longitudinal psychosocial study that forms part of the 'Identification of Men with a genetic predisposition to ProstAte Cancer: Targeted Screening in men at higher genetic risk and controls' (IMPACT) study. The IMPACT study is a multi-national study of targeted prostate cancer (PrCa) screening in individuals with a known germline pathogenic variant (GPV) in either the BReast CAncer gene 1 (BRCA1) or the BReast CAncer gene 2 (BRCA2).<BR><B>METHODS: </B>Participants enrolled in the IMPACT study were invited to complete a psychosocial questionnaire prior to each annual screening visit for a minimum of 5 years. The questionnaire included questions on sociodemographics and the following measures: Hospital Anxiety and Depression Scale, Impact of Event Scale, 36-item Short-Form Health Survey, Memorial Anxiety Scale for PrCa, Cancer Worry Scale, risk perception and knowledge.<BR><B>RESULTS: </B>A total of 760 participants completed questionnaires: 207 participants with GPV in BRCA1, 265 with GPV in BRCA2 and 288 controls (non-carriers from families with a known GPV). We found no evidence of clinically concerning levels of general or cancer-specific distress or poor health-related quality of life in the cohort as a whole. Individuals in the control group had significantly less worry about PrCa compared with the carriers; however, all mean scores were low and within reported general population norms, where available. BRCA2 carriers with previously high prostate-specific antigen (PSA) levels experience a small but significant increase in PrCa anxiety (P = 0.01) and PSA-specific anxiety (P < 0.001). Cancer risk perceptions reflected information provided during genetic counselling and participants had good levels of knowledge, although this declined over time.<BR><B>CONCLUSIONS: </B>This is the first study to report the longitudinal psychosocial impact of a targeted PrCa screening programme for BRCA1 and BRCA2 carriers. The results reassure that an annual PSA-based screening programme does not have an adverse impact on psychosocial health or health-related quality of life in these higher-risk individuals. These results are important as more PrCa screening is targeted to higher-risk groups.